Sonnet BioTherapeutics Announces FDA Acceptance of the Company’s IND for the SB221 Clinical Trial of SON-1010 Combined with Atezolizumab in the US
An IND was required to conduct the SB221 study of platinum-resistant ovarian cancer (PROC) with the combination of Sonnet's SON-1010...